Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Spartan Metals Geophysical Surveys Indicate Potential Tungsten-Silver Veins Extension at Its Tungstonia Claims, Nevada
CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
